AUTL logo

AUTL Autolus Therapeutics plc

NASDAQ Global Select · Biotechnology · Healthcare

$1.06
-0.03 (-2.75%)

Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Ad…

Market Cap: $282.32Mwww.autolus.com

Price

No data yet.

Social Signal Score

55
5d
—
30d
54
6 mentions
—
60d
57
8 mentions
—
90d
52
9 mentions
—
news: 9

Analyst Ratings

14 analysts
Buyconsensus
Strong Buy 0Buy 11Hold 3Sell 0Strong Sell 0
Avg price target$8.87+736.8%
Low $7.6Median $8High $11
Current Consensus

Revenue

$41.24M+9261.63%
$0.00$15.23M$30.46M$45.69M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.98
$-1.05–$-0.82
6 analysts
FY2026
$-0.77
$-0.87–$-0.63
5 analysts
FY2027
$-0.58
$-0.75–$-0.30
6 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Christian Martin Itin
Sector
Healthcare
Industry
Biotechnology
Employees
752
Beta
2.35
Country
GB
Piotroski score
3 / 9 (Weak)
Altman Z-score
-4.23
www.autolus.com